Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA
31/03/2026 13:43
March 31 (Reuters) - PolyPid Ltd PYPD.O: POLYPID INITIATES D-PLEX₁₀₀ NDA SUBMISSION TO THE FDA POLYPID LTD - NDA SUBMITTED UNDER FDA FAST TRACK DESIGNATION; CLINICAL SECTION EXPECTED Q2 2026 POLYPID LTD - U.S. COMMERCIALIZATION PARTNERSHIP NEGOTIATIONS FOR D-PLEX₁₀₀ ON TRACK Source text: ID:nGNXyjBWG Further company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA